Trial reportBMJ mental health2025
Efficacy of rTMS combined with tDCS in patients with major depressive disorder with anxiety: a randomised, double-blind, sham-controlled study.
Trial report in BMJ mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor depressive disorder (MDD) with comorbid anxiety presents a greater treatment challenge and higher relapse risk. Non-invasive brain stimulation techniques such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) have shown efficacy individually, but their combined effect remains unclear.
objectiveTo assess the efficacy and acceptability of rTMS, tDCS and their combined therapy in alleviating depressive and anxiety symptoms in patients with MDD.
methodsIn this double-blind, randomised, sham-controlled trial, 240 patients with MDD with anxiety symptoms were assigned to four groups: active rTMS+active tDCS, active rTMS+sham tDCS, sham rTMS+active tDCS and sham rTMS+sham tDCS. Participants received 10 sessions over 2 weeks and were followed for an additional 2 weeks. Primary outcomes were changes in Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Scale (HAMA) scores from baseline to post-treatment. χ² tests and mixed-design analysis of variance were used for group comparisons.
findingsAfter 2 weeks of treatment, the combined rTMS+tDCS group showed significantly greater reductions in HDRS scores than the other three groups. Reductions in HAMA scores were also larger compared with the sham-sham group and remained superior to that of the other groups at the 4-week follow-up. The combined group had the highest anxiety response rate (82.83%, p=0.014) and remission rate (26.17%, p=0.020) at post-treatment. No serious adverse events were reported across groups.
conclusionsCombined rTMS and tDCS were more effective than monotherapy or sham in alleviating depression and anxiety in MDD, with good tolerability and no significant side effects. CLINICAL IMPLICATIONS: This combined neuromodulation approach may serve as a promising and well-tolerated non-pharmacological option for patients with MDD with comorbid anxiety. It offers a clinically scalable intervention that could complement current first-line therapies. TRIAL REGISTRATION NUMBER: ChiCTR2100052122.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.